Symbols / CYCN Stock $2.93 -0.34% Cyclerion Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
CYCN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Regina M. Graul Ph.D.
Exch · Country NCM · United States
Market Cap 12.69M
Enterprise Value 9.14M
Income -3.53M
Sales 2.07M
FCF (ttm) -2.89M
Book/sh 2.38
Cash/sh 0.77
Employees 1
Insider 10d —
IPO Mar 18, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.24
PEG —
P/S 6.12
P/B 1.23
P/C —
EV/EBITDA —
EV/Sales 4.41
Quick Ratio 4.71
Current Ratio 5.15
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.11
EPS next Y -1.31
EPS Growth —
Revenue Growth -43.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-31
Earnings (prior) 2026-03-31
ROA -31.78%
ROE -39.34%
ROIC —
Gross Margin 53.76%
Oper. Margin -81.76%
Profit Margin -170.11%
Shs Outstand 4.33M
Shs Float 3.49M
Insider Own 24.26%
Instit Own 7.28%
Short Float 7.21%
Short Ratio 0.02
Short Interest 267.35K
52W High 8.48
vs 52W High -65.45%
52W Low 1.03
vs 52W Low 185.30%
Beta 0.89
Impl. Vol. —
Rel Volume 0.02
Avg Volume 4.72M
Volume 88.77K
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $8.00
Tgt High $8.00
# Analysts 1
Recom None
Prev Close $2.94
Price $2.93
Change -0.34%
About

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.93
Latest analyst target
3. DCF / Fair value
$-12.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.93
Low
$8.00
High
$8.00
Mean
$8.00
News
RSS: Latest CYCN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-03-25 HECHT PETER M Director and Beneficial Owner of more than 10% of a Class of Security — 181,818 $2.75 $500,000
2025-03-25 HIGGINS MICHAEL J Director — 9,090 $2.75 $24,998
2024-11-21 SLATE PATH CAPITAL LP Beneficial Owner of more than 10% of a Class of Security — 357,880 $1.55 $555,108
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.07
+3.70%
2.00
0.00
-100.00%
0.30
Operating Revenue
2.07
+3.70%
2.00
0.00
-100.00%
0.30
Operating Expense
7.05
+25.21%
5.63
-41.66%
9.65
-48.79%
18.84
Research And Development
0.96
+235.31%
0.29
-81.12%
1.51
-74.66%
5.98
Selling General And Administration
6.09
+13.96%
5.34
-34.31%
8.13
-36.76%
12.86
General And Administrative Expense
6.09
+13.96%
5.34
-34.31%
8.13
-36.76%
12.86
Other Gand A
6.09
+13.96%
5.34
-34.31%
8.13
-36.76%
12.86
Other Operating Expenses
—
—
—
-1.33
Total Expenses
7.05
+25.21%
5.63
-41.66%
9.65
-48.79%
18.84
Operating Income
-4.97
-37.07%
-3.63
+62.39%
-9.65
+47.97%
-18.54
Total Operating Income As Reported
-4.97
-37.07%
-3.63
+71.99%
-12.95
+30.15%
-18.54
EBITDA
-4.97
-37.07%
-3.63
+62.39%
-9.65
+47.78%
-18.48
Normalized EBITDA
-6.29
-57.60%
-3.99
+37.08%
-6.34
+65.67%
-18.48
Reconciled Depreciation
—
—
0.00
-100.00%
0.07
EBIT
-4.97
-37.07%
-3.63
+62.39%
-9.65
+47.97%
-18.54
Total Unusual Items
1.32
+262.81%
0.36
+110.99%
-3.30
0.00
Total Unusual Items Excluding Goodwill
1.32
+262.81%
0.36
+110.99%
-3.30
0.00
Special Income Charges
1.32
+262.81%
0.36
+110.99%
-3.30
0.00
Other Special Charges
-1.32
-262.81%
-0.36
—
—
Impairment Of Capital Assets
—
0.00
-100.00%
3.30
0.00
Net Income
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Pretax Income
-3.53
-15.41%
-3.06
+75.72%
-12.59
+30.98%
-18.25
Net Non Operating Interest Income Expense
0.13
-38.46%
0.21
-41.90%
0.36
+21.77%
0.29
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.13
-38.46%
0.21
-41.90%
0.36
+21.77%
0.29
Interest Expense
—
—
—
—
Interest Income Non Operating
0.13
-38.46%
0.21
-41.90%
0.36
+21.77%
0.29
Interest Income
0.13
-38.46%
0.21
-41.90%
0.36
+21.77%
0.29
Other Income Expense
1.32
+262.81%
0.36
+110.99%
-3.30
—
Other Non Operating Income Expenses
—
0.36
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Net Income From Continuing Operation Net Minority Interest
-3.53
-15.41%
-3.06
+75.72%
-12.59
+30.98%
-18.25
Net Income From Continuing And Discontinued Operation
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Net Income Continuous Operations
-3.53
-15.41%
-3.06
+75.72%
-12.59
+30.98%
-18.25
Net Income Discontinuous Operations
—
0.00
-100.00%
7.33
+128.38%
-25.83
Normalized Income
-4.84
-41.67%
-3.42
+63.18%
-9.29
+49.09%
-18.25
Net Income Common Stockholders
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Diluted EPS
—
-1.21
+46.22%
-2.25
+88.91%
-20.28
Basic EPS
—
-1.21
+46.22%
-2.25
+88.91%
-20.28
Basic Average Shares
—
2.52
+7.70%
2.34
+7.59%
2.17
Diluted Average Shares
—
2.52
+7.70%
2.34
+7.59%
2.17
Diluted NI Availto Com Stockholders
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Total Other Finance Cost
—
—
—
-0.29
Line Item Trend 2023-12-31
Total Assets
13.37
Current Assets
8.02
Cash Cash Equivalents And Short Term Investments
7.57
Cash And Cash Equivalents
7.57
Receivables
0.00
Accounts Receivable
0.00
Prepaid Assets
0.44
Other Current Assets
0.01
Total Non Current Assets
5.35
Net PPE
0.00
Gross PPE
0.13
Accumulated Depreciation
-0.13
Properties
—
Machinery Furniture Equipment
0.13
Other Properties
—
Leases
—
Investments And Advances
5.35
Other Investments
5.35
Other Non Current Assets
—
Total Liabilities Net Minority Interest
2.09
Current Liabilities
2.09
Payables And Accrued Expenses
1.97
Payables
1.20
Accounts Payable
1.20
Current Accrued Expenses
0.78
Pensionand Other Post Retirement Benefit Plans Current
0.00
Current Capital Lease Obligation
—
Other Current Liabilities
0.11
Total Non Current Liabilities Net Minority Interest
0.00
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Stockholders Equity
11.29
Common Stock Equity
11.29
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
2.47
Ordinary Shares Number
2.47
Treasury Shares Number
0.17
Additional Paid In Capital
275.72
Retained Earnings
-264.42
Gains Losses Not Affecting Retained Earnings
-0.01
Other Equity Adjustments
-0.01
Total Equity Gross Minority Interest
11.29
Total Capitalization
11.29
Working Capital
5.94
Invested Capital
11.29
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
11.29
Tangible Book Value
11.29
Current Notes Payable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-3.31
+23.52%
-4.33
+79.60%
-21.25
+47.69%
-40.61
Cash Flow From Continuing Operating Activities
-3.31
+23.52%
-4.33
+79.60%
-21.25
+47.69%
-40.61
Cash From Discontinued Operating Activities
—
—
-15.75
0.00
Net Income From Continuing Operations
-3.53
-15.41%
-3.06
+41.92%
-5.26
+88.06%
-44.08
Depreciation Amortization Depletion
—
—
0.00
-100.00%
0.07
Depreciation And Amortization
—
—
0.00
-100.00%
0.07
Other Non Cash Items
—
-0.36
+97.70%
-15.75
—
Stock Based Compensation
0.44
-29.44%
0.62
-41.42%
1.07
-82.93%
6.25
Asset Impairment Charge
—
0.00
-100.00%
3.30
0.00
Operating Gains Losses
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-0.23
+85.24%
-1.54
+66.57%
-4.60
-61.44%
-2.85
Change In Receivables
-0.44
+20.14%
-0.56
-679.17%
0.10
+2300.00%
0.00
Changes In Account Receivables
-0.44
+20.14%
-0.56
-679.17%
0.10
+2300.00%
0.00
Change In Prepaid Assets
0.04
+76.19%
0.02
-94.21%
0.36
+195.12%
0.12
Change In Payables And Accrued Expense
0.17
+117.54%
-1.00
+81.99%
-5.54
-60.24%
-3.46
Change In Accrued Expense
0.06
+110.31%
-0.55
+85.33%
-3.77
+18.07%
-4.60
Change In Payable
0.12
+126.52%
-0.45
+74.89%
-1.77
-255.17%
1.14
Change In Account Payable
0.12
+126.52%
-0.45
+74.89%
-1.77
-255.17%
1.14
Change In Other Current Assets
0.01
+200.00%
-0.01
-101.04%
0.48
+0.00%
0.48
Change In Other Current Liabilities
—
—
—
0.00
Investing Cash Flow
—
0.00
-100.00%
10.40
0.00
Cash Flow From Continuing Investing Activities
—
—
—
0.00
Cash From Discontinued Investing Activities
—
0.00
-100.00%
10.40
0.00
Net PPE Purchase And Sale
—
—
—
0.00
Purchase Of PPE
—
—
—
0.00
Sale Of PPE
—
—
—
0.00
Capital Expenditure
—
—
—
—
Financing Cash Flow
3.32
0.00
-100.00%
5.02
+17224.14%
0.03
Cash Flow From Continuing Financing Activities
3.32
0.00
-100.00%
5.02
+17224.14%
0.03
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
1.25
0.00
—
0.00
Common Stock Payments
-0.13
0.00
—
—
Repurchase Of Capital Stock
-0.13
0.00
—
—
Proceeds From Stock Option Exercised
—
0.00
-100.00%
5.02
+17224.14%
0.03
Net Other Financing Charges
2.08
—
—
—
Changes In Cash
0.01
+100.18%
-4.33
+25.54%
-5.82
+85.66%
-40.58
Effect Of Exchange Rate Changes
0.00
+100.00%
-0.01
-175.00%
0.01
+166.67%
0.00
Beginning Cash Position
3.23
-57.31%
7.57
-43.42%
13.38
-75.20%
53.96
End Cash Position
3.24
+0.25%
3.23
-57.31%
7.57
-43.42%
13.38
Free Cash Flow
-3.31
+23.52%
-4.33
+79.60%
-21.25
+47.69%
-40.61
Common Stock Issuance
1.38
0.00
—
0.00
Issuance Of Capital Stock
1.38
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category